The Global Demand for Global Amyotrophic Lateral Sclerosis Treatment Market in Terms of revenue was worth of USD 316.01 Million in 2020 and is expected to reach USD 436.17 Million in 2027, growing at a CAGR of 5.52% from 2021 to 2027.
The global amyotrophic lateral sclerosis treatment market is expected to grow at a significant growth rate due to number of driving factors.
Amyotrophic lateral sclerosis (ALS) is a nervous system disease that progressively degenerate the muscles and impacts physical body function. The disease is also recognized as motor neuron or Lou Gehrig's disease. The ALS mostly happens between 40-60 age groups and sometimes it can develop in early age also due to inheritance of the genetic mutation. The disease leads to the damage of nerve cells, brain and spinal cord which impact the difficulty in breathing, swallowing, speaking, and mobility. This disease is mostly of two types depending upon its cause which are sporadic and familial. The main cause of developing the ALS disease is disorganized immune response, chemical imbalance with higher levels of glutamate in the body, mishandling of proteins and some of the risk factors includes exposure to viral agents, vigorous physical activity, and trauma. Currently, no cure available for the treatment of the ALS disease but the drugs, advanced stem cell therapy and certain physical therapy can reduce the symptoms of the disease.
The study provides a crucial view of global amyotrophic lateral sclerosis treatment market by segmenting the market based on type, treatment, drug type, end-user and region & country level. Based upon type, the market is segmented into sporadic ALS and familial ALS. Based upon treatment, the market is segmented into medication, physical therapy, respiratory therapy, speech therapy and others. Based upon drug type, the market is segmented into Riluzole, Edaravone and Nuedexta. Based upon end-user, the market is segmented into hospitals, specialty centers, research & academic institutes and others.
The regions covered in global amyotrophic lateral sclerosis treatment market are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, global amyotrophic lateral sclerosis treatment market is sub divided into U.S., Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Brazil, Mexico, GCC, Africa, etc.
Factors such as increasing prevalence of amyotrophic lateral sclerosis (ALS) disease, surge in the awareness about its treatment and growing demand for personalized treatment drugs with rising geriatric populations are driving the growth of the global amyotrophic lateral sclerosis treatment market. Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that progressively degenerate the muscles and impacts physical body function. According to Centers for Disease Control and Prevention (CDC) in 2014; the prevalence of ALS was an estimated 5 cases per 100000 populations globally. The ALS disease has higher prevalence in the developed countries due to presence of sedentary lifestyle increases the risk the geriatric population, which creates a demand for novel therapeutics approaches and targeted treatment medications for ALS.
According to ALS Association, the ALS has affected between 2 and 5 people in every 100,000 worldwide whereas around 5,000 people receives a diagnosis annually. However, the high cost associated with ALS treatment may limit the market growth during the forecast period. In spite of that, rising technological advancement using artificial intelligence, advent of nanotechnology, IoT, machine learning algorithm etc. for helping the people suffering with ALS, rising public awareness, self-identification through a secure web portal refinement of the algorithm use to identify ALS cases will create huge opportunity for further growth of the ALS treatment market. For example; in 2014, in the U.S. the social media centered campaign held the ALS Ice Bucket Challenge, for increasing awareness of ALS and ultimately it has received extensive public visibility and response.
The type, segment of amyotrophic lateral sclerosis treatment market is dominated by Sporadic ALS with a largest market share of 86.35% in 2020. The treatment segment of amyotrophic lateral sclerosis treatment market report is dominated by Medication segment by capturing the largest market of XX.XX% in year 2020. The drug type segment of amyotrophic lateral sclerosis treatment market is dominated by Riluzole with a largest market share of XX.XX% in 2020. The end-user segment of amyotrophic lateral sclerosis treatment market report is dominated by Hospitals & Clinics segment by capturing the largest market of XX.XX% in year 2020.
Geographically, North America region is expected to dominate the global amyotrophic lateral sclerosis treatment market. This is due to the rising prevalence of ALS disease, sedentary lifestyle and increasing the geriatric population which has high the risk of developing this ALS disorder in this region. According to the Urban Institute report, the number of Americans age 65 and older will more than double over the next 40 years, reaching 80 million in 2040. The numbers of adults age 85 and older, the group most often needing help with basic personal care, will nearly quadruple between 2000 and 2040.
According to the Centers for Disease Control and Prevention in 2016; the prevalence of ALS was estimated between 14,500 and 15,000 people in the United States and approximately 5,000 people in the U.S. are diagnosed with ALS annually. Moreover, Asia Pacific region is expected to witness a significant growth in this market owing to the rapidly increasing geriatric population and growing need to cure with the help of suitable amyotrophic lateral sclerosis (ALS) treatment. According to National Library of Medicine organization, in Japan’s Chamorro people of Guam and people from the Kii Peninsula, the prevalence rate of developing the ALS disease of was 100 times more frequent than ALS is in other populations.
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive disorder characterized primarily by selective neurodegeneration of the motor neurons. It is a global disease, which adversely affects the life quality of patients and significantly increases the burden of families and society. It belongs to a wider group of disorders known as motor neuron diseases, which are caused by gradual deterioration (degeneration) and death of motor neurons. No cure has yet been found for ALS. However, there are treatments available that can help control symptoms, prevent unnecessary complications, and make living with the disease easier.
Some of the major trends in the global amyotrophic lateral sclerosis (ALS) treatment market are as follows:
Medication: There are currently four drugs approved by the U.S. Food and Drug Administration to treat ALS (Radicava, Rilutek, Tiglutik, and Nuedexta). Studies all over the world, many funded by The ALS Association, are ongoing to develop more treatments and a cure for ALS.
Due to the increasing cases of amyotrophic lateral sclerosis different types of therapies are also used to treat ALS. Some therapies are trending in recent years. For example:
Thus, these are some of the major trends in the global amyotrophic lateral sclerosis (ALS) treatment market.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 316.01 Million|
|Base year considered||2020|
|Forecast Period CAGR %:||5.52 %|
|Market Size Expected in 2027:||USD 436.17 Million|
|Tables, Charts & Figures:||175|
Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, Amylyx Pharmaceuticals Inc., AB Science, Biohaven Pharmaceutical, Biogen, Annexon Biosciences, MediciNova, Novartis, AL-S Pharma, Acurastem, others.
|Segments Covered||By Type, By Treatment, By End User|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|